Notably, we observed that patients with high EMP3 expression also had high expression of the immune checkpoints PD1/PDL1 and CTLA4, which may explain why immune activation was enriched in the EMP3 high subgroup, but did not hinder tumor progression. This evidence concerns the gene CTLA4 and neoplasm.